Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
Drug Saf. 2025 Jun 23.
doi: 10.1007/s40264-025-01578-x.
Online ahead of print.
1 Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Via Costantinopoli 16, 80138, Naples, Italy. raffaella.dinapoli@unicampania.it.
2 Department of Experimental Medicine-Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy. raffaella.dinapoli@unicampania.it.
3 Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team, 33000, Bordeaux, France. raffaella.dinapoli@unicampania.it.
4 Service de Rhumatologie, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpital Pellegrin, Centre Hospitalier Universitaire, Bordeaux, France.
5 CNRS-UMR 5164, ImmunoConcept, Université de Bordeaux, Bordeaux, France.
6 Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Via Costantinopoli 16, 80138, Naples, Italy.
7 Department of Experimental Medicine-Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.
8 Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
9 Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team, 33000, Bordeaux, France.
10 CHU de Bordeaux, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance Bordeaux-DROM, 33000, Bordeaux, France.